• Vaccine Name: A2-CPA-CPB(-CTE)-recombinant L. tarentolae
• Target Pathogen: Leishmania infantum
• Target Disease: Infantile visceral leishmaniasis
• Vaccine Ontology ID: VO_0004628
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Baboon
• Vector: Leishmania tarentolae vaccine vector
  • Vector name: Leishmania tarentolae vaccine vector
  • VO vector ID: VO_0001028
• Preparation: Recombinant L. tarentolae expressing the L. donovani A2 antigen along with cysteine proteinases (CPA and CPB without its unusual C-terminal extension (CPB(-CTE))) as a tri-fusion gene (Saljoughian et al., 2013).
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Vaccination Protocol: Group 1 (DNA cSLN/Live) immunized with pcDNA-A2-CPA-CPB-CTE-cSLN (50 µg of pcDNA-A2-CPA-CPB-CTE formulated by cSLN nanoparticles as a chemical delivery as previously described [59] as a prime and with 2×10^7 recombinant L. tarentolae A2-CPA-CPB-CTE as a boost; group 2 (L. tarentolae Live A2-CPA-CPB-CTE/L. tarentolae Live A2-CPA-CPB-CTE) vaccinated with 2×10^7 recombinant L. tarentolae-A2-CPA-CPB-CTE as prime and boost; group 3 (PBS as a control); group 4 [(empty vector pcDNA-cSLN (prime)/Live L. tarentolae wild type (boost) as a control)]; and group 5 (L. tarentolae Live/L. tarentolae Live) vaccinated with 2×10^7 L. tarentolae wild type as prime and boost and used as a control. All groups were immunized via footpad (Saljoughian et al., 2013).
• Vaccine Immune Response Type: VO_0003057
• Challenge Protocol: Three weeks after the last immunization, all animals were challenged with 10^7 stationary phase L. infantum promastigotes by lateral tail vein (Saljoughian et al., 2013).
• Efficacy: Our results showed that immunization with both prime-boost A2-CPA-CPB(-CTE)-recombinant L. tarentolae protects BALB/c mice against L. infantum challenge (Saljoughian et al., 2013).